Loading stock data…
Revvity (RVTY)
$110.47-2.70 (-2.39%)
Market ClosedLast close Jul 24
Revvity, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Revvity, Inc. in the Healthcare sector is trading at $110.47 with a market capitalization of $11.3B. Wall Street consensus targets $117.13 (15 analysts), implying a +6.0% move over the next 12 months. The stock is currently 7% below its 52-week high of $118.30, remaining 12.4% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +6.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $711.12M↓ | $772.06M↑ | $698.95M↓ | $720.28M↑ | $664.76M |
| Gross Profit | $387.65M↓ | $421.66M↑ | $374.60M↓ | $392.56M↑ | $375.55M |
| Operating Income | $75.89M↓ | $111.75M↑ | $81.90M↓ | $89.06M↑ | $72.23M |
| Net Income | $40.72M↓ | $98.36M↑ | $46.65M↓ | $53.95M↑ | $42.24M |
Peer Comparison
JNJUNHPFE
Fundamentals
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$11.29B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.25%
ROE
Average efficiency. Growth may require heavy reinvestment.
3.34%
Volume
Today's trading volume
883,055
Recent News
Revvity Develops High-Throughput T-SPOT.TB Platform for Clinical Labs
RVTY's T-SPOT A201 targets a 2027 launch, promising high-throughput latent TB testing with greater lab efficiency and scalability.
Revvity to Launch Signals for Startups for Emerging Biotech Companies
RVTY's Signals for Startups gives early-stage biotechs scalable software and guided onboarding to streamline research and support future growth.
Alamar Hits A High Note On Alzheimer's Buzz
If you’re an Alamar Biosciences (ALMR) shareholder, Friday was a good day. The stock climbed +7.3%, closing the session at a new 52-week high of $28.42. That’s a tidy gain on a day when the S&P 500 barely nudged up +0.4% and some key industry peers actually lost ground.
Should Revvity’s (RVTY) Claude Integration Reframe How Investors View Its Data and AI Strategy?
In early July 2026, Anthropic announced that Revvity Signals Software joined its Model Context Protocol connector directory, allowing scientists to access Signals AI and connected R&D knowledge directly through Claude, including the Claude Science workbench. This move links Claude’s reasoning tools with Revvity’s governed, ontology-driven scientific data, potentially making AI-driven discovery workflows more accessible to life sciences researchers who already rely on Revvity’s Signals...
Revvity (RVTY) Joins Anthropic Directory To Bring Claude Into Signals Research Workflows
Revvity's (NYSE:RVTY) Signals Software platform has joined Anthropic's Model Context Protocol directory. The move connects Signals AI to Anthropic's Claude models, aiming to streamline scientific data access and analysis. This development is positioned to expand how researchers interact with complex R&D datasets using AI tools. For investors watching Revvity, this news sits at the intersection of lab software and advanced AI. The company is already active in scientific research tools, and...